Takeda's oncology discovery strategy

Japanese Journal of Clinical Oncology

Volumn 43, Issue 4, 2013, Pages 357-361

  DeSchuytner, Brian ^a   Kuvalanka, Kyle ^a   Hibner, Barbara ^a   Bolen, Joseph ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Leuprorelin; Takeda oncology strategy; VELCADE

Indexed keywords

[4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; BORTEZOMIB; BRENTUXIMAB VEDOTIN; IXAZOMIB CITRATE; LEUPRORELIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ORTERONEL; PROTEIN; TAK 733; UNCLASSIFIED DRUG;

AMYLOIDOSIS; CANCER CHEMOTHERAPY; DRUG DEVELOPMENT; DRUG INDUSTRY; HODGKIN DISEASE; HUMAN; JAPAN; LARGE CELL LYMPHOMA; LEADERSHIP; MEDICAL RESEARCH; MULTIPLE MYELOMA; ONCOLOGY; PROSTATE CANCER; PROTEIN HOMEOSTASIS; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; UNITED STATES;

ANTINEOPLASTIC AGENTS; BIOLOGICAL AGENTS; CALIFORNIA; DRUG INDUSTRY; HOMEOSTASIS; HORMONES; JAPAN; PROTEINS; RESEARCH;

EID: 84875780947     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt023     Document Type: Review

References (17)

1. Takeda [Internet]. About Takeda. Corporate philosophy 2012. http:// www.takeda.com/about-takeda/corporate-philosophy/.
2. Takeda [Internet]. About Takeda. Core Products 2012. http://www.takeda.com/about-takeda/product-portfolio/article_73.html.
3. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumoral heterogeneity and branched evolution revealed by multiregion sequencing. NEJM 2012;366:883-92.
4. Marusyk A, Almendro V, Polyak K. Intratumoral heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012;12:323-34.
5. Wilson A, Meethal SV, Bowen RL, et al. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs 2007;16: 1851-63.
6. Matsui H, Tanaka A, Yokoyama K, et al. Chronic administration of the Metastin/Kisspeptin analog KISS1-305 or the investigational agent TAK-448 suppresses hypothalamic pituitary gonadal function and depletes plasma testosterone in adult male rats. Endocrinology 2012;153:5297-308.
7. Kaku T, Hitaka T, Ojida A, et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 2011;19:6383-99.
8. Yamaoka M, Hara T, Hitaka T, et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomologous monkeys. J. Steroid Biochem Mol Biol 2012;129:115- 25.
9. Ward M. Velcade's true believers. BioCentury [Internet], 2008 [cited 27 November 2012]. http://www.biocentury.com/biotech-pharma-news/ coverstory/2008-02-04/cover-story-product-development-velades-truebelievers- a1.
10. Moreau P, Richardson P, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120:947-59.
11. Cohen P, Tcherpakova M. Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 2010;143:686-93.
12. Soucy T, Smith P, Milhollen MG, et al. An inhibitor of NEDD8- activating enzyme as a new approach to treat cancer. Nature 2009;458:732-6.
13. Senter P, Sievers E. The discovery and development of brentuximab vedotin for use in relapsed Hodgkins lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30: 631-7.
14. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkins lymphoma. J Clin Oncol 2012;30:2183-9.
15. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase 2 study. J Clin Oncol 2012;30: 2190-96.
16. Dong Q, Dougan DR, Gong X, et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg Med Chem Lett 2011;21:1315-9.
17. Fulmer T. Sidebar: Intellikine's story. BioCentury, 2012 [cited 27 November 2012]. http://www.biocentury.com/biotech-pharma-news/ products/2012-02-27/Intellikinespi3k-platform-reaches-back-to-thechemistry- lab-at-ucsf-a15.